Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
- PMID: 29315510
- PMCID: PMC5947521
- DOI: 10.1002/cpt.1010
Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
Abstract
There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions.
© 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Figures
Similar articles
-
New drugs in preclinical and early stage clinical development in the treatment of heart failure.Expert Opin Investig Drugs. 2019 Jan;28(1):51-71. doi: 10.1080/13543784.2019.1551357. Epub 2018 Dec 7. Expert Opin Investig Drugs. 2019. PMID: 30523722 Review.
-
Developing New Treatments for Heart Failure: Focus on the Heart.Circ Heart Fail. 2016 May;9(5):e002727. doi: 10.1161/CIRCHEARTFAILURE.115.002727. Circ Heart Fail. 2016. PMID: 27166246
-
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.Eur J Heart Fail. 2018 Nov;20(11):1601-1610. doi: 10.1002/ejhf.1295. Epub 2018 Sep 17. Eur J Heart Fail. 2018. PMID: 30225882 Clinical Trial.
-
Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction.JACC Heart Fail. 2017 Jul;5(7):507-517. doi: 10.1016/j.jchf.2017.04.007. Epub 2017 Jun 14. JACC Heart Fail. 2017. PMID: 28624483 Clinical Trial.
-
The Role of Positive Inotropic Drugs in the Treatment of Older Adults with Heart Failure and Reduced Ejection Fraction.Heart Fail Clin. 2017 Jul;13(3):527-534. doi: 10.1016/j.hfc.2017.02.008. Epub 2017 May 2. Heart Fail Clin. 2017. PMID: 28602370 Review.
Cited by
-
DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure.Drugs Context. 2020 Feb 28;9:2019-11-3. doi: 10.7573/dic.2019-11-3. eCollection 2020. Drugs Context. 2020. PMID: 32165892 Free PMC article. Review.
-
Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future.Front Cardiovasc Med. 2024 Mar 19;11:1337154. doi: 10.3389/fcvm.2024.1337154. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38566963 Free PMC article. Review.
References
-
- Ponikowski, P . et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18, 891–975 (2016). - PubMed
-
- Yancy, C.W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147–239 (2013). - PubMed
-
- Braunschweig, F. , Cowie, M.R. & Auricchio, A. What are the costs of heart failure? Europace 13(suppl. 2), ii13–17 (2011). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous